3 Dasatinib

Preface
1 Introduction
2 TKIs for CML
3 Dasatinib
4 Asciminib
5 ELVN-001
6 TERN-701 CARDINAL Phase 1 Study Analysis
7 TGRX-678 Phase 1 Study Analysis: Efficacy in CML Patients with T315I Mutation
8 Olverembatinib
9 Additional Mutations in CML
10 BCR-ABL1 TKD mutations
11 Guideline Recommendations in CML
12 TKI Discontinuation
13 HSCT for CML
14 Summary
References

3 Dasatinib

3.1 Dasatinib 50 mg dose data Naqvi et al. (2018)

Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, et al. 2018. “Early Results of Lower Dose Dasatinib (50mg Daily) as Frontline Therapy for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” Cancer 124 (13): 2740–47. https://doi.org/10.1002/cncr.31357.

2 TKIs for CML

4 Asciminib